Agilent divests Hycor Biomedical
Life sciences firm Agilent Technologies divests its Hycor in vitro diagnostics business to private equity firm Linden LLC for undisclosed terms on Feb. 3. Hycor, which makes allergy, autoimmune and urinalysis tests, was acquired by Agilent in 2007 as part of its purchase of Stratagene. It is a "profitable and growing business but it does not fit the core focus of our life science business," Agilent explained (1"The Gray Sheet" June 11, 2007)
More from Archive
More from Medtech Insight
The roles and responsibilities of EU medtech’s persons responsible for regulatory compliance vary widely in role and risk exposure. The recent TEAM-PRRC meeting highlighted how vulnerable they can be and the steps to protect themselves.
Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test
Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.
Philips puts its latest “disappointing” warning letter into context, while announcing progress in regulatory performance, expanded US production and tariff resilience plans